Title
Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency
Multicenter, Prospective, Randomized, Double-Blind Study to Assess the Therapeutic Efficacy and Safety of the Use of Venocur Triplex® in Patients With Chronic Venous Insufficiency
Phase
Phase 4Lead Sponsor
AbbottStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Venous InsufficiencyStudy Participants
216The purpose of this study is to assess the therapeutic efficacy and safety of Venocur Triplex®, administered BID for 60 days in patients with Chronic Venous Insufficiency rated between CEAP 2 and 4, in comparison to a Placebo group.
Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
Inclusion Criteria: The patient has confirmed his/her willingness to participate in the study, after being informed about all the aspects of the study that might be relevant for his/her decision to participate, and has signed and dated the informed consent form, as approved by the Institutional Review Board/ Ethics Committee (IRB/EC) Patients of both sexes, aged above 18 years and below 65 years Presence of uni- or bilateral varicose veins with CVI, in both sexes The patient's CVI is rated between functional classes CEAP 2 and 4 Present at least one symptom of CVI prior to the study - leg pains, cramps, fatigue, heavy legs sensation. Exclusion Criteria: If female, the patient has circulatory disorders exclusively during the pre-menstrual period If the patient is pregnant or breastfeeding The patient has received anticoagulants less than 15 days before study start The patient has used steroids or anti-inflammatory drugs less than 8 days before study start The patient has received radio or chemotherapy less than 7 days before study start The patient has used diuretics, phlebotrophic and venoactive drugs over the past 8 days before enrollment in the study The patient has used compression stockings less than 8 days before study start Trauma or surgical treatment over the past 30 days before study start Prior surgical treatment related to CVI (past 12 months for surgery and past 6 months for sclerotherapy) Immobilization of lower limbs over the past 6 months Known allergy to the product's ingredients Presence of chronic inflammatory diseases (rheumatoid arthritis, for instance), severe chronic infectious diseases (AIDS, tuberculosis, hanseniasis, etc.) The patient has suffered from phlebitis or deep venous thrombosis in the past 6 months before the study Fibrous lymphedema, primary or secondary lymphedema and lipoedema; Concomitant erysipelas Active fungal infections of the lower limbs Peripheral arteries disease, cerebrovascular or coronary disease Severe systemic conditions (heart failure, liver, pulmonary or kidney failure, active neoplastic disease, severe arterial hypertension, uncontrolled diabetes, among others), over the past 6 months before study start Hematocrit: < 32.0 mL RBC/dL for women and < 36.0 mL RBC/dL for men Hemoglobin: < 11.0 mL g/dL for women and < 12.0 mL g/dL for men; Total protein and fractions: Total protein < 6.4 g/dL, Albumin < 4.0 g/dL, Globulin < 1g/dL and Albumin/Globulin < 0.9% Serum creatinine: > 1.0 mg/dL for women and > 1.2 mg/dL for men or if patient in dialysis Aminotranferases (SGOT/AST and/or SGPT/ALT) more than twice the upper normal limit Participation in study with similar objectives over the past 6 months.
